A Single-centre, Single-dose, Open Label, Non-randomized, Parallel Group, Clinical Pharmacology Study of CHF 6001 in Asthmatic Adolescent Patients and in Asthmatic Adult Patients as Control Group
Latest Information Update: 06 May 2025
At a glance
- Drugs Tanimilast (Primary) ; Tanimilast (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Chiesi Farmaceutici SpA
Most Recent Events
- 27 Apr 2025 Status changed from not yet recruiting to recruiting.
- 04 Apr 2025 New trial record